Rational Innovation

New technologies are announced almost daily, so what makes SynDevRx different?  Our technology provides the key missing ingredient to decades of polymeric drug research - essential polymer-drug linking chemistries.

We believe our compounds are the next generation of drug therapies. They combine a broad-spectrum active moiety with a unique biological target conjugated to stable, bio-compatible polymers. Restricting drug release to disease tissue concentrates activity where needed while reducing the risk of toxicities.

For more information, please contact:

Jim Shanahan

VP Business Development
617.401.3110 (office)

jshanahan@syndevrx.com

NB: SynDevRx is not affiliated with Children's Hospital Boston, and has no development program associated with Children's Hopsital.